We proceeded to validate a subset of both proto-oncogenes and tumour suppressor genes with DS events in our composite cancer signalling pathway, including PIK3CD, FGFR3, TSC2, ITGA4, MET, NF1, BAK1, ATM and RASGRP2 (Fig. 2). The gene discussed is RASGRP2; the disease is cancer.